| 翻訳と辞書 |
VSV-EBOV
The Vesicular Stomatitis Virus-Ebola Virus vaccine — known as VSV-EBOV — is an experimental vaccine for protecting against Ebola virus disease. It was developed by scientists at the National Microbiology Laboratory in Winnipeg, Canada.〔(【引用サイトリンク】title=Canada offers experimental Ebola vaccine VSV-EBOV to West Africa )〕〔(【引用サイトリンク】title=Canada's experimental Ebola vaccine: How does it work? )〕 As of July 2015 clinical trials were ongoing.
VSV-EBOV is a recombinant, replication-competent vaccine. It consists of a vesicular stomatitis virus, which has been genetically engineered to express Ebola glycoproteins so as to provoke an immune response against the complete Ebola virus.〔http://america.aljazeera.com/articles/2015/3/11/why-were-still-waiting-on-an-ebola-vaccine.html〕 The vaccine variant known as rVSV-ZEBOV, rVSV-ZEBOV-GP, VSVΔG-ZEBOV, or BPSC1001 expresses glycoproteins of the Zaire ebolavirus or ZEBOV, the species causing the highest mortality rate among the ebolaviruses, while rVSV-MARV or rVSV-MARV-GP expresse those of the closely related Marburg filovirus or MARV.
==Proposed use==
VSV-EBOV is a candidate vaccine against Ebola virus disease.〔Choi WY, et al Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res. 2015 Jan;4(1):11-6. Epub 2015 Jan 30. Review. PMID 25648233 (Free PMC 4313103 )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「VSV-EBOV」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|